Pacira Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pacira Pharmaceuticals, Inc. on March 4, 2014. The report discloses a corporate governance event regarding the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The material change reported is the appointment of Dr. Yvonne Greenstreet as a Class III director on March 4, 2014. She has been appointed to the Compensation Committee. The Board determined that Dr. Greenstreet is independent under Nasdaq listing standards.
Outlook, Risks, and Management Commentary
Management highlighted Dr. Greenstreet's extensive background, including over 20 years of global pharmaceutical experience. She currently serves as Senior Vice President and Head of Medicines Development at Pfizer, Inc., and previously held senior roles at GlaxoSmithKline plc. She will receive the Company's standard compensation for non-employee directors. No specific risks, contingencies, or unusual items were disclosed in this filing.
Key Facts for Investor Verification
- Dr. Yvonne Greenstreet was appointed as a Class III director on March 4, 2014.
- She has been assigned to the Compensation Committee.
- The Board confirmed her independence status under Nasdaq standards.
- Her compensation will align with the standard package for non-employee directors.
- No financial results or operational metrics are included in this specific filing.